

# 1 Immunogenicity and safety of a third dose, and immune persistence of

## 2 CoronaVac vaccine in healthy adults aged 18-59 years: interim results

### 3 from a double-blind, randomized, placebo-controlled phase 2 clinical

#### 4 trial

5

6 Hongxing Pan MSc<sup>1\*</sup>, Qianhui Wu MPH<sup>2\*</sup>, Gang Zeng Ph.D.<sup>3\*</sup>, Juan Yang Ph.D.<sup>1</sup>, Deyu

7 Jiang MSc<sup>4</sup>, Xiaowei Deng MSc<sup>2</sup>, Kai Chu MSc<sup>1</sup>, Wen Zheng BSc<sup>2</sup>, Fengcai Zhu M.D.<sup>5†</sup>,

8 Hongjie Yu M.D. Ph.D.<sup>2,6,7†</sup>, Weidong Yin MBA<sup>8†</sup>

9

#### 10 Affiliations

- 11 1. Vaccine Evaluation Institute, Jiangsu Provincial Center for Disease Control and
- 12 Prevention, Nanjing, China
- 13 2. School of Public Health, Fudan University, Key Laboratory of Public Health Safety,
- 14 Ministry of Education, Shanghai, China
- 15 3. Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China
- 16 4. Covid-19 Vaccine Department, Sinovac Life Sciences Co., Ltd., Beijing, China
- 17 5. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China
- 18 6. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University,
- 19 Shanghai, China
- 20 7. Department of Infectious Diseases, Huashan Hospital, Fudan University,
- 21 Shanghai, China
- 22 8. Sinovac Biotech Co., Ltd., Beijing, China

23

24     \*: These authors contributed equally.

25     †: These authors jointly supervised this work.

26

27     **Corresponding to** Fengcai Zhu, Jiangsu Provincial Center for Disease Control and

28     Prevention, Nanjing 210000, China, Email: [jszfc@vip.sina.com](mailto:jszfc@vip.sina.com); Hongjie Yu, School of

29     Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of

30     Education, Shanghai 200032, China, E-mail: [yhj@fudan.edu.cn](mailto:yhj@fudan.edu.cn); Weidong Yin, Sinovac

31     Biotech Co., Ltd., Beijing 100085, China, Email: [yinwd@sinovac.com](mailto:yinwd@sinovac.com).

32

33     Word count (abstract): 383

34     Word count (main text): 3265

## 35 **Abstract**

## 36 **Background**

37 Large-scale vaccination is being implemented globally with CoronaVac, an inactivated  
38 vaccine against coronavirus disease 2019 (COVID-19). Immunogenicity and safety  
39 profiles of homologous two-dose schedules have been published. We report interim  
40 results of immune persistence, and the immunogenicity and safety of a third dose of  
41 CoronaVac.

## 42 **Methods**

43 In this ongoing, placebo-controlled, double-blind phase 2 trial in 18-to-59-year-olds,  
44 we randomly assigned subjects, 1:1:1:1, to one of four schedules to receive a third  
45 dose, 28 days or 6 months after two two-dose regimens (14-day or 28-day apart):  
46 ***schedule 1***: days 0, 14, 42; ***schedule 2***: days 0, 14, 194; ***schedule 3***: days 0, 28, 56;  
47 ***schedule 4***: days 0, 28, 208. For each schedule, participants were randomly assigned  
48 to either a medium-dose group (3 µg per 0.5 mL of aluminum hydroxide diluent per  
49 dose), a high-dose group (6 µg), or a placebo group (2:2:1). The primary outcome  
50 was geometric mean titers (GMTs) of neutralizing antibody to live SARS-CoV-2.

## 51 **Results**

52 Overall, 540 participants received a third dose. In the 3 µg group, neutralizing  
53 antibody titers induced by the first two doses declined after 6-8 months to below the  
54 seropositive cutoff (GMT: 4.1 [95%CI 3.3-5.2] for ***Schedule 2*** and 6.7 [95%CI 5.2-8.6]  
55 for ***Schedule 4***). When a third dose was given 6-8 months after a second dose, GMTs  
56 assessed 14 days later increased to 137.9 [95%CI 99.9-190.4] for ***Schedule 2***, and  
57 143.1 [95%CI 110.8-184.7] for ***Schedule 4***, approximately 3-fold above ***Schedule 1***

58 and **Schedule 3** GMTs after third doses. Similar patterns were observed for the 6 µg  
59 group. The severity of solicited local and systemic adverse reactions reported within  
60 28 days after the third dose were grade 1 to grade 2 in all vaccination cohorts. None  
61 of the fourteen serious adverse events were considered to be related to vaccination.

## 62 **Conclusions**

63 A third dose of CoronaVac administered 6 or more months after a second dose  
64 effectively recalled specific immune response to SARS-CoV-2, resulting in a  
65 remarkable increase in antibody levels, and indicating that a two-dose schedule  
66 generates good immune memory. Optimizing the timing of a booster dose should  
67 take into account immunogenicity, vaccine efficacy/effectiveness, local epidemic  
68 situation, infection risk, and vaccine supply. (Funded by the National Key Research  
69 and Development Program, Beijing Science and Technology Program and National  
70 Science Fund for Distinguished Young Scholars; ClinicalTrials.gov number,  
71 NCT04352608.)

## 72 Introduction

73 In response to the coronavirus disease 2019 (COVID-19) pandemic, twenty COVID-19  
 74 vaccines have been approved for use<sup>1</sup> and more than 3.73 billion doses have been  
 75 administered as of July 20, 2021<sup>2</sup>. Real-world evidence has shown that vaccination  
 76 effectively reduces SARS-CoV-2 transmission<sup>3</sup> and decreases COVID-19 burden of  
 77 disease<sup>4-6</sup>. A hope and expectation are that herd immunity can be achieved through  
 78 mass vaccination to curb the pandemic. Amid the ongoing effort to vaccinate target  
 79 populations, two critical questions are of great interest to scientists and  
 80 policy-makers developing strategies to stop the pandemic: how durable is  
 81 vaccine-induced immunity, and will people need a booster dose? And if so, when will  
 82 people need a booster dose?

83

84 CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine against  
 85 COVID-19, has been authorized for conditional use in China<sup>7</sup> and is included in the  
 86 World Health Organization's (WHO) emergency use listing<sup>8</sup>. CoronaVac has been  
 87 administered in 26 countries<sup>1</sup> and is increasing the supply of COVID-19 vaccines  
 88 through COVAX<sup>9</sup>. In China, a total of 1.46 billion doses COVID-19 vaccines have been  
 89 administered as of July 19<sup>10</sup>, the vast majority of which are inactivated vaccines.

90

91 Evidence from real-world use of CoronaVac with a two-dose schedule in Chile  
 92 demonstrated that the vaccine effectively prevents laboratory-confirmed COVID-19,  
 93 and with highest effectiveness against the more severe outcomes (hospitalization,  
 94 ICU admission, and death)<sup>11</sup>. However, persistence of CoronaVac vaccine-induced

immunity is unknown, and the immunogenicity and safety of a booster dose has not been determined. We report relevant findings from an ongoing phase 2 clinical trial of CoronaVac; we compare immunogenicity and safety of a third homologous dose given at an interval of 6 months or more following the second dose to an alternative schedule with a dose-2 to dose-3 interval of 28 days.

100

## 101 **Methods**

### 102 ***Study design and participants***

Our single-center, double-blind, randomized, placebo-controlled, phase 2 clinical trial of CoronaVac was initiated in Jiangsu, China on May 3, 2020, with two two-dose schedules in the original protocol. Healthy adults aged 18-59 years were eligible for enrollment. Exclusion criteria can be found in a previous publication<sup>12</sup>. Eligible participants were recruited and randomly allocated (1:1) to schedules with either a 14-day interval or a 28-day interval; within each schedule group, subjects were randomly allocated to either a medium-dose group (3 µg per 0.5 mL of aluminum hydroxide diluent per dose), a high-dose group (6 µg per 0.5 mL of aluminum hydroxide diluent per dose), or a placebo group (2:2:1). Interim results on safety, tolerability, and immunogenicity for these two doses have been reported<sup>12</sup>.

113

In June, 2020, the trial protocol was amended to evaluate the immunogenicity of an additional dose either 28 days or 6 months after the second dose (randomly allocated 1:1) in each of the original study groups. Accordingly, four regimens with three doses are included in this analysis: 1) the first two doses on days 0 and 14, and a third dose on day 42 (***schedule 1***); 2) the first two doses on days 0 and 14, plus a

119 third dose 6 months after the second dose (day 194; ***schedule 2***); 3) the first two  
 120 doses on days 0 and 28, and a third dose on day 56 (***schedule 3***); 4) the first two  
 121 doses on days 0, and 28, plus one-dose 6 months after the second dose (day 208;  
 122 ***schedule 4***). We assessed duration of immune persistence for the first two doses and  
 123 evaluated immunogenicity and safety of the third doses.

124

125 Written informed consent was obtained from participants before enrolment and  
 126 before administration of the third dose. The clinical trial protocol and informed  
 127 consent forms were approved by the Jiangsu Ethics Committee (JSJK2020-A021-02).  
 128 This trial is registered with ClinicalTrials.gov, NCT04352608. Our study was conducted  
 129 in accordance with the requirements of Good Clinical Practices of China and the  
 130 International Conference on Harmonization.

131

### 132 ***Randomization and masking***

133 Randomization codes for each vaccination schedule cohort were generated  
 134 individually; the process of assignment was described previously<sup>12</sup>. Participants in  
 135 each cohort were randomly assigned using block randomization with a block size of  
 136 five, developed with SAS software (version 9.4). Concealed random grouping  
 137 allocations and blinding codes were kept in signed and sealed envelopes and were  
 138 blinded to investigators, participants, and laboratory staff.

139

### 140 ***Procedures***

141 Vaccine or placebo was given by intramuscular injection. Procedures for the first two  
 142 doses have been described previously<sup>12</sup>. In ***schedule 1***, routine hematological and

143 biochemical tests were performed for the first 30 participants before dose 3 and  
 144 within 3 days after dose 3. Participants would not be assigned a third dose if the  
 145 severity of hematology and biochemistry indexes was grade 2 or more. Additional  
 146 exclusion criteria for administration of the third dose are provided in Appendix 1.  
 147  
 148 After successful safety observations within 3 days after dose 3 in these 30  
 149 participants, the trial could proceed and the first 30 participants in ***schedule 3*** were  
 150 allowed to be given their third dose (having passed haematological and biochemical  
 151 criteria). After successful safety observations within 7 days after dose 3 with no  
 152 abnormalities for haematological and biochemical tests, the remaining participants in  
 153 ***schedule 1*** and ***schedule 3*** groups were given dose 3. For all participants in ***schedule***  
 154 ***2*** and ***schedule 4***, a booster dose was given on the basis of interim immunogenic  
 155 results obtained 6 months after the second dose. Participants would be removed  
 156 from the trial if any of the following criteria were met: 1) participant request, 2)  
 157 unacceptable adverse event, 3) unacceptable health status, 4) abnormal clinical  
 158 manifestations judged by the investigators, 5) other reasons considered by the  
 159 investigator. The trial would be suspended under the following conditions: 1)  
 160 occurrence of one or more grade 4 (local and systemic) adverse reactions related to  
 161 vaccination; 2) more than 15% of the participants having grade 3 or above adverse  
 162 reactions, including local reactions, systemic reactions, and vital sign changes.  
 163  
 164 To evaluate immunogenicity, blood samples were collected on days 0, 28, 42, 70, and  
 165 222 from participants in the ***schedule 1*** group; on days 0, 28, 42, 194, and 208 in the  
 166 ***schedule 2*** group; on days 0, 56, 84, and 236 in the ***schedule 3*** group; and on days 0,



167 56, 208, and 236 in the ***schedule 4*** group. The timing of each visit is shown in  
 168 Appendix 2. The immunological assessment methods and related procedures were  
 169 described previously<sup>12</sup>. Neutralizing antibodies to live SARS-CoV-2 (virus strain  
 170 SARS-CoV-2/human/CHN/CN1/2020, GenBank number MT407649.1) were quantified  
 171 using a micro cytopathogenic effect assay<sup>12</sup>.

172

173 Collection of safety information after the third dose was conducted using the same  
 174 methods as for the first two doses, described previously<sup>12</sup>. Participants were required  
 175 to record injection-site adverse events (e.g., pain, redness, swelling), or systemic  
 176 adverse events (e.g., allergic reaction, cough, fever) on diary cards within 7 days after  
 177 the third dose. From days 8-28 after the third dose, unsolicited adverse reactions  
 178 were collected by spontaneous reporting from participants. Serious adverse events  
 179 were collected until 6 months after the second dose for ***schedule 2*** and ***4*** groups, and  
 180 until 6 months after three doses for ***schedule 1*** and ***3*** groups. Reported adverse  
 181 events were graded according to China National Medical Products Administration  
 182 guidelines<sup>12</sup>. Existence of causal associations between adverse events and  
 183 vaccination was determined by the investigators.

184

## 185 ***Outcomes***

186 The primary outcome was geometric mean titers (GMTs), seropositivity, and  
 187 seroconversion rate of neutralizing antibodies to live SARS-CoV-2. We defined  
 188 seropositivity as a titer of 8 or higher for neutralizing antibodies to live SARS-CoV-2.  
 189 Seroconversion was defined as a change of titers from seronegative at baseline to  
 190 seropositive, or a four-fold increase of titers for individuals whose titers were above

191 seropositive cutoffs.

192

193 A secondary analysis of safety endpoints included any adverse reactions within 28  
194 days after dose 3, and serious adverse events coded by Medical Dictionary for  
195 Regulatory Activities (MedDRA) System Organ Class during the aforementioned  
196 observation period.

197

### 198 ***Statistical analyses***

199 We assessed immunogenic endpoints in the per-protocol population (datasets at  
200 each visit are described in Appendix 3), which included all participants who  
201 completed their assigned vaccinations. Incidence of serious adverse events was  
202 evaluated in a safety population who received at least one dose of study vaccine  
203 from the beginning of the vaccination schedule; incidence of adverse reactions was  
204 evaluated in the safety population for each dose.

205

206 We used Pearson  $\chi^2$  test or Fisher's exact test to analyze categorical outcomes. We  
207 calculated 95% CIs for all categorical outcomes using the Clopper-Pearson method.  
208 We calculated GMTs and corresponding 95% CIs on the basis of standard normal  
209 distribution of log-transformed antibody titers. We used t-test to compare  
210 log-transformed antibody titers between groups. Hypothesis testing was two-sided  
211 and we considered p values of less than 0.05 to be significant. We used R software  
212 (version 3.6.0) for all analyses.

213

214 The clinical trial is supervised by an independent data monitoring committee, which

215 consists of one independent statistician, one clinician, and one epidemiologist.

216

## 217 **Results**

### 218 ***Participants***

219 We randomly assigned 150 participants to each schedule group, and within each  
220 schedule group, 60 participants were assigned at random to a 3 µg group, 60  
221 participants were assigned at random to a 6 µg group, and 30 participants were  
222 assigned at random to a placebo group; in all, 540 participants were eligible and  
223 allocated to receive third doses. In the ***schedule 2*** and ***schedule 4*** cohorts, 147 and  
224 138 participants were followed up for 6 months after the second dose, and 141 and  
225 130 participants were given third doses at 180-to-240-day intervals after the second  
226 dose for immunogenetic evaluations. In the ***schedule 1*** and ***schedule 3*** cohorts, 139  
227 and 130 participants received third doses, and 135 and 124 participants completed  
228 blood sampling to assess immune persistence for 6 months after dose 3 (Figure 1).

229

230 A subject in the 6 µg group of ***schedule 2*** received a second dose of placebo by  
231 mistake and was excluded from immunogenicity analyses. There were 143 minor  
232 protocol deviations in ***schedule 2***, including two subjects given second doses at a  
233 13-day interval after the first dose (instead of 14 days) and 141 subjects given third  
234 doses at intervals from 249-251 days after the second dose. All subjects were  
235 included in immunogenicity analyses and analyzed according to their actual  
236 situations. The mean age of participants was 44.1 years, 40.8 years, 41.2 years, 42.2  
237 years in the four schedule groups (***schedules 1-4***). More women (53.8%) than men

238 participated. Baseline characteristics are shown in Table 1.

239

## 240 ***Immunogenicity***

241 At baseline, none of the participants had detectable neutralizing antibodies in the 3

242 µg, or 6 µg groups, regardless of schedule. In the placebo group, other than 2 of 30

243 (6.67%) participants in ***schedule 2***, no participants had detectable neutralizing

244 antibodies at any of the blood-drawing visits. Given that the 3 µg formulation is the

245 licensed formulation, we present results for the 3 µg group in the main text and

246 provide detailed results for the 6 µg group in the Supplement.

247

248 On day 28 after the first two doses, GMTs were consistent between ***Schedule 1*** and

249 ***Schedule 2*** with a dose spacing of 14 days (22.2 [95%CI 17.8-27.8] vs. 25.6 [95%CI

250 20.9-31.4]). Compared with these groups, higher GMTs were observed in both

251 ***Schedule 3*** and ***Schedule 4*** with their longer dose spacing of 28 days (39.6 [95%CI

252 30.1-52.2] and 49.1 [95%CI 40.1-60.2]). However, for all two-dose schedules,

253 regardless of dose spacing, neutralizing antibody titers declined to below the

254 seropositive cutoff after 6 or more months (GMT: 4.1 [95%CI 3.3-5.2] for ***Schedule 2***,

255 and 6.7 [95%CI 5.2-8.6] for ***Schedule 4***). Even though a third dose on day 28 after the

256 first two doses slightly-to-moderately increased neutralizing antibody levels (GMT on

257 day 28 after dose 3: 45.8 [95%CI 35.7-58.9] for ***Schedule 1***, and 49.7 [95%CI 39.9-61.9]

258 for ***Schedule 3***), neutralizing antibodies decayed to close to the seropositive cutoff 6

259 months later. If a third dose was given 6 months or more after the second dose, the

260 GMT assessed 14 days after the third dose increased to 137.9 [95%CI 99.9-190.4] for

261 ***Schedule 2***, and 143.1 [95%CI 110.8-184.7] for ***Schedule 4***), approximately 3-fold

262 above that of **Schedule 1** and **Schedule 3** after their third doses (Figure 2, Table S1).  
 263  
 264 Seropositivity in all four schedules was above 90.0% on day 28 after both the second  
 265 dose and third dose. On day 180 after the third dose for **schedule 1** and **schedule 3**,  
 266 seropositivity remained above 60% while only 16.9% and 35.2% of participants in  
 267 **schedule 2** and **schedule 4** were seropositive 180 days after the second dose (Figure  
 268 2, Table S1). The seroconversion rate on day 14 after the third dose for **schedule 2**  
 269 was 100 % and on day 28 after the third dose for **schedule 4** was 95.9% (using  
 270 neutralization antibody level before the third dose as a baseline) (Table S3).

271  
 272 Similar patterns were observed for the 6 µg group. Significant differences in GMT  
 273 were observed between the 3 µg and 6 µg group in only a few visits for the four  
 274 schedules during the study time (Table S2, Figure S1, Figure S2).

275

## 276 ***Reactogenicity and safety***

277 The severity of solicited local and systemic adverse reactions reported within 28 days  
 278 after the third dose were grade 1 to grade 2 in all vaccination cohorts. The most  
 279 common reported reaction was injection-site pain (Figure 3). Incidences of adverse  
 280 reactions after the third dose were 7.91% and 3.08% for **schedule 1** and **schedule 3**,  
 281 lower than the overall incidence of adverse reactions within 28 days after three  
 282 doses (33.33% for **schedule 1** and 22.00% for **schedule 3**). In the 3 µg group, the  
 283 overall incidence of adverse reactions with 28 days after the third dose was ten  
 284 (18.18%) of 55 participants in **schedule 2** and ten (19.23%) of 52 in **schedule 4**, which  
 285 was similar with the highest incidence of adverse reactions for **schedule 1** (18.33%

286 after the first dose) and **schedule 3** (18.33% after the first dose). Most adverse  
287 reactions were grade 1 in severity. There were no significant differences among the 3  
288 µg, 6 µg, and placebo groups for all schedules (Table S4-S11).

289

290 A total of fourteen serious adverse events among nine participants were reported  
291 from the beginning of vaccination to 6 months after the second dose for **schedule 2**  
292 and **4**, and to 6 months after the third dose for **schedule 1** and **3** (Table S12). None of  
293 the serious adverse events were considered by the investigators to be related with  
294 vaccination.

295

## 296 **Discussion**

297 Our results demonstrated that two doses of CoronaVac (3 µg formulation) induce  
298 good immunogenicity. Although neutralizing antibody levels declined to near the  
299 positive cutoff titer of 8 after 6 months, a two-dose vaccination schedule generated  
300 good immune memory. A third dose, given at an interval of 6-8 months after the  
301 second dose, led to a strong boost in immune response, with GMTs increasing to  
302 approximately 140. Such an increase corresponds to 3-5 fold increase in neutralizing  
303 antibody titers 28 days after the second dose, indicating an anamnestic memory B  
304 cell response<sup>13</sup>.

305

306 SARS-CoV-2 spike-specific memory B cells are detectable in most COVID-19 patients  
307 and in all SARS-CoV-2 naïve subjects after receiving a second dose of mRNA  
308 vaccine<sup>14, 15</sup>. The third dose of CoronaVac effectively boosts neutralizing titers and  
309 potentially provides better immuno-protection. This pattern is consistent with a

310 recent study that reported booster immunization of AstraZeneca ChAdOx1 nCoV-19,  
311 showing higher concentrations of total IgG antibodies after a third dose<sup>16</sup>. We found  
312 that giving a third dose too early (28 days after the second dose) induced a much  
313 lower antibody level - only one third compared with a third dose given 6 or more  
314 months after a second dose. As shown in COVID-19 patients, memory B cells against  
315 SARS-CoV-2 spike were more abundant at 6 months than at 1 month after symptom  
316 onset<sup>14</sup>.

317

318 For the Moderna mRNA-1273 vaccine, antibody declined slightly as expected, but  
319 remained high in all ages on days 90 and 180 after the second dose, with antibody  
320 detected among all participants<sup>17,18</sup>. For Pfizer BNT162b2 and AstraZeneca ChAdOx1  
321 nCoV-19 vaccines, antibody levels declined by 55% and 84% between 21–41 days and  
322 70 days or more after a second dose<sup>19</sup>. However, it is difficult to directly compare  
323 these estimates with our findings for CoronaVac due to heterogeneity of  
324 neutralization assays. Even with neutralization assays that use the same live virus,  
325 given the lack of standardized laboratory methods for SARS-CoV-2 neutralization and  
326 experimental procedures, including virus titration, serum dilution, virus-serum  
327 neutralization, readout, and reporting method (e.g., NT50, NT100), results vary  
328 greatly by laboratory<sup>20</sup>.

329

330 During the first three months of Chile's mass vaccination campaign, a two-dose  
331 CoronaVac schedule showed good effectiveness against COVID-19: 65.9% for  
332 symptomatic infection, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3%  
333 for death among a population aged 16 years or older<sup>11</sup>. Our study demonstrated that

334 the neutralizing antibody level decayed to around the positive cutoff of 8 by 6-8  
335 months after the second dose. Vaccine effectiveness in this case is unclear, since the  
336 protection threshold of titers against COVID-19 remains unknown, and both T cell  
337 immunity and B cell memory against SARS-CoV-2 elicited by inactivated vaccines may  
338 contribute to protection<sup>13,21</sup>. In addition, establishment of SARS-CoV-2 spike-specific  
339 immune memory, other than inducing durable antibody, may be important for a  
340 successful COVID-19 vaccine<sup>12</sup>. In epidemic areas with SARS-CoV-2 circulation,  
341 natural infection after two-dose vaccination may play the role of a booster dose<sup>22</sup>.  
342 Accordingly, although a third dose of CoronaVac would be essential, the timing of a  
343 booster dose must account for the local epidemic situation, risk of infection, vaccine  
344 supply, and other relevant factors. In the short-to-medium term, ensuring more  
345 people complete the current two-dose schedule of CoronaVac should be the priority.  
346  
347 CoronaVac is approved for use in a two-dose schedule with an interval of 14-28 days  
348 between doses. In our study, dose spacing impacted immunogenicity. A longer  
349 interval between the first and second doses triggered a stronger immune response  
350 (28 days vs. 14 days: about 2-fold GMT on day 28 after the second dose, and 2-fold  
351 seropositivity at 6 months after the second dose), as has been seen with other  
352 COVID-19 vaccines, such as ChAdOx1-S, and BNT162b2<sup>23,24</sup>.  
353  
354 The incidence of adverse reactions after the third dose was lower than the highest  
355 incidence of adverse reactions during the observation period in a previous study<sup>12</sup>.  
356 That study found a 24.2% incidence after the first dose in the days 0 and 14 schedule,  
357 indicating that a third dose was well-tolerated. Although no major safety concern



358 was identified during our trial, adverse reactions are important to monitor in  
359 large-scale clinical trials and during post-marketing periods.

360

361 Our study had several limitations. First, T cell responses were not assessed in the  
362 phase 2 trial. Second, we only reported immune response data for healthy adults,  
363 and did not include individuals who are more susceptible, have higher risk of severe  
364 outcomes, but have lower neutralizing antibody titers after two-dose vaccination  
365 (e.g., older individuals [aged ≥ 60 years] or with comorbidities)<sup>25,26</sup>. Data on immune  
366 persistence needs further study, particularly immune persistence of a third dose  
367 given 6 months or more after the second dose. Third, although there were no  
368 tolerability concerns reported from those receiving a third dose, the sample size in  
369 our study is not sufficiently large to assess rare vaccine side effects. Fourth, we did  
370 not perform neutralization test in vitro against variants to determine the  
371 neutralization ability of the vaccine to emerging variants of concern.

372

373 In summary, our study found that a two-dose vaccination schedule of CoronaVac (3  
374 µg formulation) generated good immune memory. Although the neutralizing  
375 antibody titer dropped to low levels 6 months after the second dose, a third dose  
376 was highly effective at recalling a SARS-CoV-2-specific immune response, leading to a  
377 significant rebound in antibody levels. Determining the timing of a booster dose must  
378 take into account many factors, including immunogenicity, vaccine  
379 efficacy/effectiveness, the epidemic situation, risk of infection, and vaccine supply.

## **Declarations**

### **Competing interests**

H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. None of those research funding is related to development of COVID-19 vaccines. G.Z. and W.Y. were the employees of Sinovac Biotech Ltd., D.J. was an employee of Sinovac Life Sciences Co., Ltd. All other authors report no competing interests.

### **Funding**

The study was supported by grants from National Key Research and Development Program (2020YFC0849600), Beijing Science and Technology Program (Z201100005420023), and National Science Fund for Distinguished Young Scholars (81525023).

### **Acknowledgements**

We thanked Dr. Lawrence Everett Rodewald from Chinese Center for Disease Control and Prevention for his kind comments on this paper.

## References

1. COVID-19 Vaccine Market Dashboard.  
<https://www.unicef.org/supply/covid-19-vaccine-market-dashboard> Accessed 21 July 2021.
2. Our world in Data. <https://ourworldindata.org/covid-vaccinations> Accessed 22 July 2021.
3. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household Transmission of SARS-CoV-2 in England. *The New England journal of medicine* 2021.
4. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New England Journal of Medicine* 2021;384:1412-23.
5. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet (London, England)* 2021;397:1819-29.
6. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet (London, England)* 2021;397:1646-57.
7. China Food and Drug Administration. Conditional use approval for CoronaVac.  
<https://www.nmpa.gov.cn/yaopin/ypjgd/20210206154636109.html>.
8. Kremsner P, Mann P, Bosch J, et al. Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers. *medRxiv* 2020:2020.11.09.20228551.
9. COVAX Global Supply Forecast. July 12, 2021.  
<https://www.gavi.org/sites/default/files/covid/covax/COVAX-Supply-Forecast.pdf>  
Accessed 21 July 2021.
10. COVID-19 vaccination. National Health Commission of the People's Republic of China. [http://www.gov.cn/xinwen/2021-07/20/content\\_5626149.htm](http://www.gov.cn/xinwen/2021-07/20/content_5626149.htm) Accessed July 21, 2021.
11. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine* 2021.
12. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases* 2021;21:181-92.
13. Quast I, Tarlinton D. B cell memory: understanding COVID-19. *Immunity* 2021;54:205-10.
14. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021;371.
15. Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci Immunol* 2021;6.
16. Flaxman A, Marchevsky N, Jenkin D, Aboagye J, Aley PK. Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19

(AZD1222). ssrn 2021.

17. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine* 2021.
18. Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *New England Journal of Medicine* 2021;384.
19. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. *Lancet (London, England)* 2021.
20. Chen X, Chen Z, Azman AS, et al. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination. *medRxiv : the preprint server for health sciences* 2021.
21. Deng Y, Li Y, Yang R, Tan W. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients. *Cell Mol Immunol* 2021.
22. Chen H, Mao Y, Duan Z, et al. Three Cases of COVID-19 Variant Delta With and Without Vaccination — Chengdu City, Sichuan Province, April–May, 2021. *China CDC Weekly* 2021;3:544-6.
23. Voysey M, Clemens SAC, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet (London, England)* 2021;397:881-91.
24. Parry H, Bruton R, Stephens C, et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. *medRxiv* 2021.
25. Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol* 2021;22:765-78.
26. Maneikis K, Šablauskas K, Ringelevičiūtė U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. *Lancet Haematol* 2021.

## Figure Legends

### Figure 1. Study Profile

† One participant received the second dose on day 13, which was one day ahead of the schedule specified in the protocol. \*Participants received the third dose between day 249 and day 251, exceeding the time window specified in the protocol (day 180+60).

### Figure 2. Level of neutralizing antibodies to live SARS-CoV-2 in 3 µg group: A)-B) days 0 and 14 vaccination cohort; C)-D) days 0 and 28 vaccination cohort


Note: Data are represented as reciprocal neutralizing antibody titers regarding the time after the first dose in per-protocol population. Numbers above the bars show the Geometric Mean Titer (GMT), and the error bars indicate the 95% CI. Statistical differences were assessed by t-test on log-transformed data. \*p<0.05, \*\*p<0.005, \*\*\*p<0.0005, \*\*\*\*p<0.0001.

### Figure 3. Incidence of selected adverse reactions within 28 days after the third dose.


**Table 1. Baseline demographic characteristics for the safety population**

	3 µg group	6 µg group	Placebo group
<b>Days 0, 14, 42 vaccination cohort (<i>schedule 1</i>)</b>			
Participants	60	60	30
Age, years	44.9±8.9	43.7±8.8	43.5±8.3
Sex (Male/Female)	29/31	21/39	13/17
<b>Days 0, 14, 194 vaccination cohort (<i>schedule 2</i>)</b>			
Participants	60	60	30
Age, years	39.0±10.7	41.1±9.1	43.6±7.0
Sex (Male/Female)	25/35	27/33	12/18
<b>Days 0, 28, 56 vaccination cohort (<i>schedule 3</i>)</b>			
Participants	60	60	30
Age, years	41.0±9.1	40.1±9.9	43.9±7.4
Sex (Male/Female)	36/24	33/27	12/18
<b>Days 0, 28, 208 vaccination cohort (<i>schedule 4</i>)</b>			
Participants	60	60	30
Age, years	42.0±10.2	41.1±10.0	44.7±9.5
Sex (Male/Female)	27/33	30/30	12/18


### A. Schedule 1: Days 0, 14, 42 vaccination cohort




### C. Schedule 3: Days 0, 28, 56 vaccination cohort







### B. Schedule 2: Days 0, 14, 194 vaccination cohort







### D. Schedule 4: Days 0, 28, 208 vaccination cohort









■ Grade 1 ■ Grade 2